Ferrous Bisglycinate as a well-tolerated API against Iron Deficiency Anemia
Dr. Paul Lohmann® is the world's first manufacturer of Ferrous Bisglycinate as an active pharmaceutical ingredient (API), which is available including the API documentation (DMF/ASMF) for the registration of a drug with the health authorities.
Ferrous Bisglycinate is a fully reacted Iron Salt based on glycine with a low heavy metal content and an improved solubility and dissolution profile.1 The glycine chelate structure protects the highly reactive Iron from redox reactions in the gastrointestinal tract and thus prevents unpleasant side effects such as epigastric pain, nausea, vomiting and abdominal cramps.2 Due to its high bioavailability and tolerance during use, Ferrous Bisglycinate is ideally suited as an API for the treatment of Iron deficiency anemia and for the prevention of Iron status disorders in pregnant women and breastfeeding mothers.3
References:
1 Name, J. J., et al. Iron Bisglycinate Chelate and Polymaltose Iron for the Treatment of Iron Deficiency Anemia: A Pilot Randomized Trial; 2018, 14(4), 261-268.
2. Ferrari, P., et al. Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate. Biomedicine & Pharmacotherapy, 2012, 66(6), 414-418.
3. Soppi, E. T. Iron deficiency without anemia – a clinical challenge, Clinical Case Reports, 2018, 6(6), 1082-1086.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News Women in Pharma: The Final Chapter of 2025
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and ... -
News Introducing the Pharmaceutical Sustainability Ecosystem from CPHI
The Sustainability Collective from CPHI unveils the groundbreaking Pharmaceutical Sustainability Ecosystem to drive pharmaceutical knowledge sharing, connection, and collaboration in order to change the face of sustainability in pharmceutical... -
News Navigating Cross-Border Pharmaceutical Logistics: Strategies for a More Resilient Supply Chain
This is a feature article written by Nick Fryer, Vice President of Marketing, Sheer Logistics
-
News A Day in the Life of a Director of Business Development
In this Day in the Life of interview, Thomas Hauser, Director of Business Development at Tjoapack. Thomas has spent nearly 30 years in the pharmaceutical industry and describes how he still finds curiosity and excitement in the bigger picture of global... -
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Say hello to the CPHI Exhibitor Spotlight!
We’re kicking off a brand-new series where we shine the spotlight on some of the amazing companies gearing up to shake things up at CPHI Americas 2025 this May! The first company in our spotlight is TAPI, who are set to make a splash at its ve...